Propanc Biopharma plans Phase 1b cancer trial, posts $18.9M net loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Propanc Biopharma plans Phase 1b cancer trial, posts $18.9M net loss

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

September 29, 2026 8:30 AM EDT

MELBOURNE, Australia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (Propanc or the Company), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported year-end financial results as of June 30, 2026 (Year end June 30).

CORPORATE HIGHLIGHTS

To commence a world-first Phase 1b FIH study of PRP in Q1, 2027

The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at trial centers across... More